Viatris Looks To Call It A Day In US Januvia, Janumet Patent Saga
ANDA Sponsor And Originator Merck Look To Settle Hatch-Waxman Case
Executive Summary
Viatris and Merck have disclosed plans to settle litigation currently pending before the US Court of Appeals for the Federal Circuit over the ANDA sponsor’s generic versions of its sitagliptin-containing medicines, Januvia (sitagliptin) and Janumet (sitagliptin/metformin).
You may also be interested in...
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Viatris Loses US Challenge To Januvia And Janumet Patents
Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.
Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.